Use of continuous infusion ceftolozane-tazobactam with therapeutic drug monitoring in a patient with cystic fibrosis
| Autor: | Sarah Elizabeth B Davis, Julie Ann Justo, P. Brandon Bookstaver, Jennifer Hucks, David P. Nicolau, Jared Ham, Rachel A Foster, Alyssa P. Gould |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Drug
Adult Tazobactam Cystic Fibrosis media_common.quotation_subject medicine.disease_cause Cystic fibrosis Drug Administration Schedule Pulmonary function testing 03 medical and health sciences 0302 clinical medicine Drug Resistance Multiple Bacterial Escherichia coli Medicine Humans Pseudomonas Infections 030212 general & internal medicine Respiratory system Infusions Intravenous Escherichia coli Infections media_common Pharmacology 0303 health sciences medicine.diagnostic_test 030306 microbiology business.industry Pseudomonas aeruginosa Health Policy medicine.disease Anti-Bacterial Agents Cephalosporins Regimen Treatment Outcome Therapeutic drug monitoring Pharmacodynamics Anesthesia Female Drug Monitoring business |
| Zdroj: | American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. 76(8) |
| ISSN: | 1535-2900 |
| Popis: | PurposeThe safe and effective use of ceftolozane–tazobactam delivered via continuous infusion in a cystic fibrosis (CF) patient with reduced body weight and presumed augmented renal clearance is reported.SummaryA 30-year-old woman with CF was admitted for acute pulmonary exacerbations with positive respiratory cultures for Pseudomonas aeruginosa and extended-spectrum β-lactamase-producing Escherichia coli. Susceptibility testing confirmed multidrug resistance, and the patient was transitioned to ceftolozane–tazobactam for definitive therapy. A novel strategy of administering ceftolozane–tazobactam 6 g by continuous i.v. infusion over 24 hours was initiated during hospitalization and continued at discharge for a total of 10 days. Therapeutic drug monitoring over the first 36 hours of the continuous infusion confirmed adequate exposure. The patient had clinical resolution with return to baseline of pulmonary function tests and no noted adverse drug events.ConclusionA continuous infusion regimen of ceftolozane–tazobactam was successfully used in a CF patient with augmented renal clearance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|